May 7th, 2015
Selections from Richard Lehman’s Literature Review: May 7th
Richard Lehman, BM, BCh, MRCGP
This week’s topics are a comparison of a retrievable inferior vena cava filter plus anticoagulation vs. anticogulation alone for recurrent PE, the cost effectiveness and population impact of statins for primary prevention in U.S. adults age 75 and older, and more.
April 28th, 2015
No Advantage to Adding Inferior Vena Cava Filters to Anticoagulation
Larry Husten, PHD
Despite a lack of supporting evidence many patients with acute venous thromboembolism (VTE) receive inferior vena cava filters to prevent pulmonary embolism (PE). Now a new study published in JAMA offers no evidence of benefit for the use of these devices in a high-risk population already receiving anticoagulant drugs. A group of French physicians randomized nearly 400 […]
June 17th, 2014
A Meta-Look at Thrombolysis vs. Conventional Anticoagulation for PE
Jay Giri, MD, MPH and Saurav Chatterjee, MD
Jay Giri and Saurav Chatterjee discuss their meta-analysis of trials comparing thrombolytic therapy and conventional anticoagulation in patients at intermediate risk for pulmonary embolism.
June 17th, 2014
Mixed Results for Thrombolysis in Pulmonary Embolism
Larry Husten, PHD
The role of thrombolytic therapy for the treatment of pulmonary embolism has been unclear, as it has been difficult to measure the precise balance between enhanced clot-dissolving efficacy and greater bleeding risk produced by thrombolysis when compared with conventional anticoagulation. A new meta-analysis published in JAMA analyzed data from 16 randomized trials including 2115 patients. Overall, […]
April 14th, 2014
Selections from Richard Lehman’s Literature Review: April 14th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include TOPCAT, fibrinolysis for those with intermediate-risk PE, and more.
March 24th, 2014
Selections from Richard Lehman’s Literature Review: March 24th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include non-leg venous thrombosis in critically ill adults, a comparison of factor Xa inhibitors and warfarin for preventing stroke and thromboembolism in atrial fibrillation, and more.
March 20th, 2014
Pulmonary Embolism in a Patient with Acute Decompensated Systolic Heart Failure
Ian Neeland, MD and James Fang, MD
Ian Neeland presents our latest case: A 42-year-old man with heart failure is found to have a large pulmonary embolus. Tell us how you’d manage his treatment.
March 6th, 2014
Vena Cava Filters Reduce Pulmonary Emboli But Increase VTE Recurrence Tenfold
Inferior vena cava filters seem to offer protection against death from pulmonary embolism when compared with anticoagulant therapy, but they have no significant effect on all-cause mortality. In addition, the filters are associated with higher rates of recurrent venous thromboembolism, according to an article in the Journal of the American College of Cardiology. Researchers examined data […]
December 18th, 2013
New Trial Confirms Role for Dabigatran in Venous Thromboembolism
Larry Husten, PHD
A new study helps support a role for the new oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) in patients with venous thrombosis (VTE). The RE-COVER II trial, published online in Circulation, confirms the finding of the earlier and highly similar RE-COVER trial, published in the New England Journal of Medicine in 2009, that dabigatran is as safe and effective as warfarin for […]
September 25th, 2013
Is It Safe to Treat Acute Pulmonary Embolism in an Outpatient Setting?
Christopher Kabrhel, MD MPH
Christopher Kabrhel discusses his research group’s study of the factors associated with clinical deterioration and the need for hospital-based interventions after an acute pulmonary embolism.